DBV Technologies (DBVT) Depreciation & Amortization (CF) (2020 - 2026)
DBV Technologies (DBVT) reported Depreciation & Amortization (CF) of $900000.0 for Q1 2026, down 10.0% year-over-year from $1.0 million in Q1 2025, and up 30.43% on a QoQ basis from $690000.0 in Q4 2025.
DBV Technologies (DBVT) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $900000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 10.0% year-over-year to $900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 13963.64% YoY) and the FY2025 annual result came in at $3.2 million, up 445.3% from the prior year.
- Depreciation & Amortization (CF) grew to $900000.0 in Q1 2026 per DBVT's latest filing, from $690000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $12.0 million in Q4 2022 and bottomed at -$10.9 million in Q4 2023.
- The 5-year median for Depreciation & Amortization (CF) is $597000.0 (2023), against an average of $137235.3.
- The widest annual swing landed in 2023, when Depreciation & Amortization (CF) sank 3056.88%; it then surged 1786.79% in 2025.
- Tracing DBVT's Depreciation & Amortization (CF) over 5 years: stood at $12.0 million in 2022, then slumped by 190.88% to -$10.9 million in 2023, then jumped by 105.84% to $638000.0 in 2024, then increased by 8.15% to $690000.0 in 2025, then soared by 30.43% to $900000.0 in 2026.
- Per Business Quant, the three latest DBVT Depreciation & Amortization (CF) figures stand at $900000.0 (Q1 2026), $690000.0 (Q4 2025), and $792000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 900,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | 690,000.00 |
| Dec 31, 2025 | 690,000.00 |
| Sep 30, 2025 | 792,000.00 |
| Sep 30, 2025 | 792,000.00 |
| Jun 30, 2025 | 712,000.00 |
| Jun 30, 2025 | 712,000.00 |
| Mar 31, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 638,000.00 |
| Dec 31, 2024 | 638,000.00 |
| Sep 30, 2024 | -152,000.00 |
| Sep 30, 2024 | -152,000.00 |
| Jun 30, 2024 | -1.46 Mn |
| Jun 30, 2024 | -1.46 Mn |
| Mar 31, 2024 | 53,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | -10.93 Mn |
| Dec 31, 2023 | -10.93 Mn |
| Sep 30, 2023 | -3.44 Mn |
| Sep 30, 2023 | -3.44 Mn |
| Jun 30, 2023 | 597,000.00 |
| Jun 30, 2023 | 597,000.00 |
| Mar 31, 2023 | -228,000.00 |
| Mar 31, 2023 | -228,000.00 |
| Dec 31, 2022 | 12.02 Mn |
| Dec 31, 2022 | 12.02 Mn |
| Sep 30, 2022 | -109,000.00 |
| Sep 30, 2022 | -109,000.00 |
| Jun 30, 2022 | 1.85 Mn |
| Jun 30, 2022 | 1.85 Mn |
| Mar 31, 2022 | -599,000.00 |
| Mar 31, 2022 | -599,000.00 |
| Dec 31, 2021 | -1.33 Mn |
| Dec 31, 2021 | -1.33 Mn |
| Sep 30, 2021 | 1.09 Mn |
| Sep 30, 2021 | 1.09 Mn |
| Jun 30, 2021 | 7.14 Mn |
| Jun 30, 2021 | 7.14 Mn |
| Mar 31, 2021 | 1.48 Mn |
| Mar 31, 2021 | 1.48 Mn |
| Dec 31, 2020 | -7.90 Mn |
| Dec 31, 2020 | -7.90 Mn |
| Sep 30, 2020 | 3.77 Mn |
| Sep 30, 2020 | 3.77 Mn |
| Mar 31, 2020 | 1.55 Mn |
| Mar 31, 2020 | 1.55 Mn |